A key future direction involves health economic studies to demonstrate that the long-term benefits of earlier CKD detection and intervention with cystatin C, such as reduced progression to end-stage renal disease and lower healthcare costs, outweigh the initial higher test cost. Here, CST3 is linked to stage 5 chronic kidney disease.